THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. StemCell Technologies, Inc. - and – Oxford...Supply Agreement • November 5th, 2013 • Oxford Immunotec Global PLC • In vitro & in vivo diagnostic substances • British Columbia
Contract Type FiledNovember 5th, 2013 Company Industry JurisdictionTHIS AGREEMENT dated as of 31st January, 2008 between OXFORD IMMUNOTEC LTD., a corporation incorporated under the laws of the United Kingdom having its principal place of business in Abingdon, Oxfordshire, United Kingdom (“Oxford”) and STEMCELL TECHNOLOGIES, INC., a corporation incorporated under the laws of British Columbia and Canada having its principal place of business in Vancouver, British Columbia, Canada (“StemCell”).
THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. Marketing Authorization Holder AgreementMarketing Authorization Holder Agreement • November 5th, 2013 • Oxford Immunotec Global PLC • In vitro & in vivo diagnostic substances
Contract Type FiledNovember 5th, 2013 Company IndustryThis is an agreement (the “Agreement”) made on and effective as of July 29, 2011 by and between Oxford Immunotec Limited, a company organized and existing under the laws of UK, address at 94C Milton Park, Abingdon, Oxfordshire OX14 4RY United Kingdom (hereinafter referred to as “MANUFACTURER”, and RIKEN GENESIS CO., LTD., a company organized and existing under the laws of Japan, address at 1-5-1 Taito, Taito-ku, Tokyo 110-8560, Japan (hereinafter referred to as “MAH”).
THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. AMENDMENT TO MARKETING AUTHORIZATION HOLDER...Marketing Authorization Holder Agreement • November 5th, 2013 • Oxford Immunotec Global PLC • In vitro & in vivo diagnostic substances
Contract Type FiledNovember 5th, 2013 Company IndustryThis Amendment (“Amendment 1”) is made this 1st day of September, 2013, by and between Oxford Immunotec Limited, a company organized and existing under the laws of UK, address at 94C Milton Park, Abingdon, Oxfordshire OX14 4RY United Kingdom (hereinafter referred to as “MANUFACTURER”, and RIKEN GENESIS CO., LTD., a company organized and existing under the laws of Japan, address at 1-5-1 Taito, Taito-ku, Tokyo 110-8500. Japan (hereinafter referred to as “MAH”)